Nadolol

Sold as Corgard. Every FDA application for this active ingredient: 1 branded and 14 generic.

As of Nov 14, 2026, FDA lists 15 applications for Nadolol (sold as Corgard), first approved Dec 10, 1979, with 2 new uses approved and 0 published complete response letters.

First approved: Dec 10, 1979
Applications: 15
New uses approved: 2
Complete response letters: 0
Medicare spending, 2025: $13.2M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name


Nadolol	Part D	$13.2M	-10%	62,233
Corgard	Part D	$0K	-100%	0

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

NADOLOL 20 MG TABLET: $0.127 per unitGeneric · 0% in a year
NADOLOL 40 MG TABLET: $0.254 per unitGeneric · -1% in a year
NADOLOL 80 MG TABLET: $0.316 per unitGeneric · +11% in a year

Clinical Trials

4 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


MEdical Treatment in Idiopathic Ventricular Fibrillation PatientsIdiopathic Ventricular Fibrillation, Cardiac Arrest, Out-Of-Hospital · Bo Gregers Winkel	Phase 4	Recruiting	Feb 12, 2026
Pre-emptive RTO for An Early Detected Gastric Varices in CT/MR Angiogram TrialGastric Varices · University of California, Los Angeles	Not applicable	Recruiting	Sep 11, 2025
Exercise as an Immune Adjuvant for Allogeneic Cell TherapiesLeukemia, Hematopoetic Stem Cell Transplantation · University of Arizona	Early phase 1	Recruiting	Oct 16, 2024
A Preliminary Study for INFORMEDHeart Failure, Heart Failure, Diastolic · Weill Medical College of Cornell University	Phase 4	Recruiting	Oct 18, 2022

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Dec 10, 1979	CorgardNDA 18063 · New molecular entity	Uswm	56	Discontinued
Oct 31, 1993	NadololANDA 74172	Rising	6	Marketed
Aug 31, 1994	NadololANDA 74368	Teva Pharms	4	Discontinued
Nov 9, 1995	NadololANDA 74501	Sandoz	5	Marketed
Jan 24, 1996	NadololANDA 74255	Heritage Pharma	9	Discontinued
Aug 30, 1996	NadololANDA 74229	Heritage Pharma	10	Discontinued
Sep 16, 2015	NadololANDA 201893	Aurobindo Pharma	3	Marketed
Dec 18, 2015	NadololANDA 203455	Invagen Pharms	1	Marketed
Jun 2, 2017	NadololANDA 208832	Amneal Pharms Co	1	Marketed
Jul 28, 2017	NadololANDA 207761	Zydus Pharms	1	Marketed
Oct 5, 2017	NadololANDA 209309	Chartwell Rx	0	Marketed
Jun 1, 2018	NadololANDA 210786	Ingenus Pharms LLC	1	Discontinued
Jul 23, 2018	NadololANDA 210955	Regcon Holdings	1	Marketed
Sep 13, 2019	NadololANDA 212856	Somerset Theraps LLC	0	Marketed
Jun 2, 2023	NadololANDA 211763	Alembic	1	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA